The prognostic significance of HER3 in ovarian carcinoma remains controversial; while some studies associate high expression with poorer outcomes, others have found no significant correlation or even a trend toward improved survival in certain patient subsets [29,30]. This evidence concerns the gene ERBB3 and ovarian carcinoma.